Cargando…

平均红细胞体积≤100 fl是骨髓原始细胞<5%骨髓增生异常综合征患者的独立预后因素

OBJECTIVE: To explore the prognostic effects of mean corpuscular volume (MCV) in patients with myelodysplastic syndromes (MDS). METHODS: 321 newly diagnosed, untransfused primary MDS patients who administered from December 2009 to December 2017 were enrolled. The association of MCV with prognosis an...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357904/
https://www.ncbi.nlm.nih.gov/pubmed/32023751
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.01.006
_version_ 1783558750499504128
collection PubMed
description OBJECTIVE: To explore the prognostic effects of mean corpuscular volume (MCV) in patients with myelodysplastic syndromes (MDS). METHODS: 321 newly diagnosed, untransfused primary MDS patients who administered from December 2009 to December 2017 were enrolled. The association of MCV with prognosis and several clinical features and genetic mutations were analyzed. RESULTS: Patients were divided into MCV≤100 fl (n=148) and MCV>100 fl (n=173) cohorts. Median overall survival of patients with MCV≤100 fl was shorter than their counterparts (27 months vs 72 months, P<0.001). In subgroup analysis, MCV≤100 fl patients had worse survivals in bone marrow blast <5% cohort (34 months vs not reached, P=0.002), but not so in ≥5 % cohort (17 months vs 20 months, P=0.078). MCV≤100 fl was still an independent adverse variable (HR=1.890, 95%CI 1.007–3.548, P=0.048) after adjusting for clinical and laboratory variables and mutation topography in bone marrow blasts<5% cohort. In bone marrow blasts<5% cohort, patients with MCV≤100 fl had higher hemoglobin levels [90 (42–153) g/L vs 78.5 (28–146) g/L, P=0.015].The proportions of Revised International Prognostic Scoring System (IPSS-R) high/very high risks and poor/very poor IPSS-R karyotypes were higher in MCV≤100 fl cohort (28.8% vs 10.8%, P=0.003; 24.7% vs 12.9%, P=0.049). MCV≤100 fl cohort had more genetic mutations than those with MCV>100 fl though without significance (0.988 vs 0.769, P=0.064). Mutated SF3B1 was less frequently in MCV≤100 fl cohort (4.7% vs 15.4%, P=0.018). CONCLUSION: MCV≤100 fl was an independent adverse variable after adjusting for clinical and laboratory variables and mutation topography in MDS patients with bone marrow blasts<5%.
format Online
Article
Text
id pubmed-7357904
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73579042020-07-16 平均红细胞体积≤100 fl是骨髓原始细胞<5%骨髓增生异常综合征患者的独立预后因素 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore the prognostic effects of mean corpuscular volume (MCV) in patients with myelodysplastic syndromes (MDS). METHODS: 321 newly diagnosed, untransfused primary MDS patients who administered from December 2009 to December 2017 were enrolled. The association of MCV with prognosis and several clinical features and genetic mutations were analyzed. RESULTS: Patients were divided into MCV≤100 fl (n=148) and MCV>100 fl (n=173) cohorts. Median overall survival of patients with MCV≤100 fl was shorter than their counterparts (27 months vs 72 months, P<0.001). In subgroup analysis, MCV≤100 fl patients had worse survivals in bone marrow blast <5% cohort (34 months vs not reached, P=0.002), but not so in ≥5 % cohort (17 months vs 20 months, P=0.078). MCV≤100 fl was still an independent adverse variable (HR=1.890, 95%CI 1.007–3.548, P=0.048) after adjusting for clinical and laboratory variables and mutation topography in bone marrow blasts<5% cohort. In bone marrow blasts<5% cohort, patients with MCV≤100 fl had higher hemoglobin levels [90 (42–153) g/L vs 78.5 (28–146) g/L, P=0.015].The proportions of Revised International Prognostic Scoring System (IPSS-R) high/very high risks and poor/very poor IPSS-R karyotypes were higher in MCV≤100 fl cohort (28.8% vs 10.8%, P=0.003; 24.7% vs 12.9%, P=0.049). MCV≤100 fl cohort had more genetic mutations than those with MCV>100 fl though without significance (0.988 vs 0.769, P=0.064). Mutated SF3B1 was less frequently in MCV≤100 fl cohort (4.7% vs 15.4%, P=0.018). CONCLUSION: MCV≤100 fl was an independent adverse variable after adjusting for clinical and laboratory variables and mutation topography in MDS patients with bone marrow blasts<5%. Editorial office of Chinese Journal of Hematology 2020-01 /pmc/articles/PMC7357904/ /pubmed/32023751 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.01.006 Text en 2020年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
平均红细胞体积≤100 fl是骨髓原始细胞<5%骨髓增生异常综合征患者的独立预后因素
title 平均红细胞体积≤100 fl是骨髓原始细胞<5%骨髓增生异常综合征患者的独立预后因素
title_full 平均红细胞体积≤100 fl是骨髓原始细胞<5%骨髓增生异常综合征患者的独立预后因素
title_fullStr 平均红细胞体积≤100 fl是骨髓原始细胞<5%骨髓增生异常综合征患者的独立预后因素
title_full_unstemmed 平均红细胞体积≤100 fl是骨髓原始细胞<5%骨髓增生异常综合征患者的独立预后因素
title_short 平均红细胞体积≤100 fl是骨髓原始细胞<5%骨髓增生异常综合征患者的独立预后因素
title_sort 平均红细胞体积≤100 fl是骨髓原始细胞<5%骨髓增生异常综合征患者的独立预后因素
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357904/
https://www.ncbi.nlm.nih.gov/pubmed/32023751
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.01.006
work_keys_str_mv AT píngjūnhóngxìbāotǐjī100flshìgǔsuǐyuánshǐxìbāo5gǔsuǐzēngshēngyìchángzōnghézhēnghuànzhědedúlìyùhòuyīnsù
AT píngjūnhóngxìbāotǐjī100flshìgǔsuǐyuánshǐxìbāo5gǔsuǐzēngshēngyìchángzōnghézhēnghuànzhědedúlìyùhòuyīnsù
AT píngjūnhóngxìbāotǐjī100flshìgǔsuǐyuánshǐxìbāo5gǔsuǐzēngshēngyìchángzōnghézhēnghuànzhědedúlìyùhòuyīnsù
AT píngjūnhóngxìbāotǐjī100flshìgǔsuǐyuánshǐxìbāo5gǔsuǐzēngshēngyìchángzōnghézhēnghuànzhědedúlìyùhòuyīnsù
AT píngjūnhóngxìbāotǐjī100flshìgǔsuǐyuánshǐxìbāo5gǔsuǐzēngshēngyìchángzōnghézhēnghuànzhědedúlìyùhòuyīnsù
AT píngjūnhóngxìbāotǐjī100flshìgǔsuǐyuánshǐxìbāo5gǔsuǐzēngshēngyìchángzōnghézhēnghuànzhědedúlìyùhòuyīnsù
AT píngjūnhóngxìbāotǐjī100flshìgǔsuǐyuánshǐxìbāo5gǔsuǐzēngshēngyìchángzōnghézhēnghuànzhědedúlìyùhòuyīnsù
AT píngjūnhóngxìbāotǐjī100flshìgǔsuǐyuánshǐxìbāo5gǔsuǐzēngshēngyìchángzōnghézhēnghuànzhědedúlìyùhòuyīnsù
AT píngjūnhóngxìbāotǐjī100flshìgǔsuǐyuánshǐxìbāo5gǔsuǐzēngshēngyìchángzōnghézhēnghuànzhědedúlìyùhòuyīnsù
AT píngjūnhóngxìbāotǐjī100flshìgǔsuǐyuánshǐxìbāo5gǔsuǐzēngshēngyìchángzōnghézhēnghuànzhědedúlìyùhòuyīnsù
AT píngjūnhóngxìbāotǐjī100flshìgǔsuǐyuánshǐxìbāo5gǔsuǐzēngshēngyìchángzōnghézhēnghuànzhědedúlìyùhòuyīnsù
AT píngjūnhóngxìbāotǐjī100flshìgǔsuǐyuánshǐxìbāo5gǔsuǐzēngshēngyìchángzōnghézhēnghuànzhědedúlìyùhòuyīnsù